Abstract
Randomised control trials (RCTs) do not always reflect real-life outcomes for glucose-lowering drugs. In this work we compared RCT and real-life data on the efficacy of the dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin or sulfonylureas when added to metformin.
Original language | English |
---|---|
Pages (from-to) | 1304-1307 |
Journal | Diabetologia |
Volume | 57 |
Issue number | 7 |
DOIs | |
Publication status | Published - 2014 |
Subject classification (UKÄ)
- Endocrinology and Diabetes